



Obesity Medications in Clinical Trials

What's coming next · Data as of October 2026 · All investigational, not FDA approved

	Reta-trutide Eli Lilly	Bima-grumab Eli Lilly	Cagri-lintide Novo Nordisk	MariTide Amgen	Survo-dutide Boehringer Ingelheim / Zealand	Elora-lintide Eli Lilly	Amycretin Novo Nordisk	Petre-lintide Zealand / Roche	Olato-repatide Hansoh / Regeneron	Trevo-grumab Regeneron
Mechanism	GLP + GLP-1 + glucagon agonist ("triple G") · weekly	Blocks activin type II receptors, preserving and building muscle · IV	Amylin agonist · weekly + sema-glutide = CagriSema	GLP-1 agonist + GIP antagonist · monthly	Glucagon + GLP-1 agonist · weekly	Amylin receptor agonist · weekly	One molecule acting on GLP-1 + amylin receptors	Amylin agonist · weekly	GLP-1 + GIP agonist (like tirzepatide) · weekly	Blocks myostatin, preserving muscle · given with sema-glutide
Trial	TRIUMPH Phase 3	BELIEVE Phase 2b	REDEFINE Phase 3	MARITIME Phase 2 → 3	SYNCHRO-NIZE-1 Phase 3	ENLIGHTEN Phase 3 (began 2026)	Early trial Phase 1b/2a	ZUPREME-1 Phase 2	China trial Phase 3	COURAGE Phase 2
Weight loss	-28.3% at 80 wk (12 mg) -30.3% at 104 wk (extension)	-20% with sema-glutide -10% alone Fat mass: -42% combo, -25% alone	-22.7% as CagriSema -11.8% alone vs tirzepatide: 23% vs 25.5%	-20% at 52 wk (no diabetes)	-16.6% at 76 wk	-20% at 48 wk (9 mg, Phase 2)	-24.3% at 36 wk	-10.7% at 42 wk	-19.3% at 48 wk (top dose)	No added weight loss vs sema-glutide alone
Most common side effects	Nausea 42% Diarrhea 32% Dys-esthesia 12.5%	Muscle spasms, diarrhea % not reported	CagriSema: Nausea 55% Constipation 31%	Nausea, vomiting % not reported	Nausea 65% Vomiting 45%	Nausea 64% Fatigue 46% (6 mg)	Nausea, vomiting % not reported	Nausea 20% Vomiting 3% (placebo 6%)	Nausea <10% Vomiting <5%	Nausea, constipation % not reported
Stopped due to side effects	11.3%	14–21% alone, 5–13% combo	CagriSema 5.9% Alone 2.6% (1.0% for nausea)	~11%	24.8%	not reported	not reported	1.5% (GI side effects)	not reported	not reported
Notes	—	Muscle mass: +2.5% alone -3% combo -7% sema-glutide alone	—	No weight-loss plateau seen	—	—	Small, early study	GI side effects close to placebo	Global trials start late 2026	Kept ~70% of thigh muscle lost on sema-glutide (MRI)
Expected	2027–2028	Several years	CagriSema: late 2026 Alone: several years	2028	2027–2028	TBD	TBD	TBD	TBD	Several years

Much of this data is company-reported and not yet fully peer-reviewed. Trials differ in length and population, so numbers aren't directly comparable. Dates are estimates.